Across TCGA pan-cancer cohorts, LINC02613 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LINC02613 data layer compared with 19 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LINC02613 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LINC02613 expression acts as an unfavorable survival marker.
HNSC and COAD are the cancer types where LINC02613 Mutation most reproducibly stratifies survival.